After delivering groundbreaking analytical enhancements in biopharmaceutical workflows for proteins, peptides, and oligonucleotides, Agilent is ready to do it again with the expansion of our Altura HPLC column portfolio. We’re excited to further your biopharmaceutical development with Ultra Inert technology for more analyses—including columns for aggregate, size, and intact protein analysis.
Be the first to experience the next generation of Altura columns. Complete the form to get notified when they are available.
The AdvanceBio SEC portfolio was designed to minimize hydrophilic interactions between analytes and the stationary phase. Soon the portfolio is getting an Ultra Inert glow up so you won’t have to worry about metal interactions any longer.
With secondary interactions effectively designed-out, your method conditions become more flexible. You can focus on optimizing conditions relevant to your samples, instead of mitigating interactions with your SEC column, to develop a robust platform method.
Reversed-phase LC/MS is a staple technique for molecular weight determination for intact proteins and their impurities, as well as for drug-to-antibody ratio analysis for antibody-drug conjugates.
Without silica, polymeric PLRP-S offers excellent peak shape under formic acid mobile phase conditions, while the 1000 Å pore size is well suited for efficient protein separations. As seen for peptide analysis, an Ultra Inert upgrade improves peak shape and sample recovery for metal-sensitive analytes, while reducing column conditioning time to a fraction of the time needed for conventional stainless steel columns.
Experience the difference with Altura HPLC columns. Our Ultra Inert technology sets a new standard in liquid chromatographic performance, providing the reliability and efficiency you need for your most demanding applications.
Choose Altura columns and elevate your analytical results to new heights.
DE-015017